LON:VAL ValiRx Final Earnings Report GBX 0.15 +0.01 (+3.45%) As of 11:09 AM Eastern ProfileEarnings History ValiRx EPS ResultsActual EPS-GBX 1.45Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AValiRx Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AValiRx Announcement DetailsQuarterFinalDate6/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ValiRx Earnings HeadlinesValiRx Streamlines Operations and Sharpens Strategy as Auditors Highlight Funding Uncertainty (VAL)June 23, 2026 | uk.finance.yahoo.comTRADING UPDATES: Maintel fundraising completes; ValiRx ends dealJune 22, 2026 | lse.co.ukTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.July 14 at 1:00 AM | Stansberry Research (Ad)ValiRx tightens focus and cuts costs as auditors flag going-concern riskJune 22, 2026 | tipranks.comValiRx Ends Dundee Evaluation After Cancer Asset Fails Licensing CriteriaJune 22, 2026 | tipranks.comValiRx Strengthens Cytolytix IP Portfolio with European Patent Grant and New Oncology Filings (VAL)May 27, 2026 | uk.finance.yahoo.comSee More ValiRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ValiRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ValiRx and other key companies, straight to your email. Email Address About ValiRxValiRx (LON:VAL) accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.View ValiRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity YetJPMorgan’s Q2 Strength Gives the Stock Rally New SupportPrepare for the Next Wave of Factory Automation With These 3 Standout NamesAnalysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of Style Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
